Evidence map›Paper›PMID 42132624›Full record

Observational studyJournal of radiation research2026

Optimal combination of heart and lung dose parameters in radiotherapy for locally advanced non-small cell lung carcinoma: a multicenter retrospective study.

Tomohiko Miyazaki, Koichi Yasuda, Hiroshi Taguchi, Hideki Minatogawa, Tetsuya Inoue, Rikiya Takashina, Manami Otsuka, Keiji Nakazato, Noriaki Nishiyama, Keiji Kobashi and 6 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tomohiko MiyazakiDepartment of Radiation Oncology, Graduate School of Medicine and Faculty of Medicine Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.ORCID 0009-0002-2124-0292
Koichi YasudaDepartment of Radiation Oncology, Graduate School of Medicine and Faculty of Medicine Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.ORCID 0000-0002-6333-3051
Hiroshi TaguchiDepartment of Radiation Oncology, Hokkaido University Hospital, NHO Hokkaido Cancer Center and Obihiro Kosei Hospital, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.ORCID 0000-0003-2348-4071
Hideki MinatogawaDepartment of Radiation Oncology, Hokkaido University Hospital, NHO Hokkaido Cancer Center and Obihiro Kosei Hospital, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.ORCID 0000-0002-2793-4749
Tetsuya InoueDepartment of Radiology, Obihiro Kosei Hospital, West 15, South 10, Obihiro, Hokkaido 080-0024, Japan.
Rikiya TakashinaDepartment of Radiation Oncology, Graduate School of Medicine and Faculty of Medicine Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Manami OtsukaDepartment of Radiation Oncology, Hokkaido University Hospital, NHO Hokkaido Cancer Center and Obihiro Kosei Hospital, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.
Keiji NakazatoDepartment of Medical Physics, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.
Noriaki NishiyamaDepartment of Radiation Oncology, Hokkaido University Hospital, NHO Hokkaido Cancer Center and Obihiro Kosei Hospital, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.ORCID 0000-0001-8932-4033
Keiji KobashiGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.ORCID 0000-0002-5471-8128
Izuru OtakeDepartment of Radiation Oncology, Graduate School of Medicine and Faculty of Medicine Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Jun Sakakibara-KonishiDepartment of Respiratory Medicine, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.
Satoshi OizumiDepartment of Respiratory Medicine, Hokkaido University Hospital, NHO Hokkaido Cancer Center and Obihiro Kosei Hospital, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.
Hajime KikuchiDepartment of Respiratory Medicine, Obihiro Kosei Hospital, West 15, South 10, Obihiro, Hokkaido 080-0024, Japan.
Takayuki HashimotoGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.ORCID 0000-0001-5276-3665
Hidefumi AoyamaDepartment of Radiation Oncology, Graduate School of Medicine and Faculty of Medicine Hokkaido University, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.ORCID 0000-0002-8437-7491

Funding

JSPS KAKENHI JP22H03008
6 · The paper itself

Abstract

This study aimed to identify the optimal combination of heart and lung dose parameters associated with overall survival (OS) in patients with locally advanced non-small cell lung carcinoma (LA-NSCLC) receiving radiotherapy. Data from 278 patients treated definitively for LA-NSCLC at three institutions between 1 April 2013 and 31 October 2021 were retrospectively analyzed. Lung and heart dose parameters were categorized into high- or low-dose groups based on predefined thresholds for subsequent analysis. Univariable analysis of OS was conducted for all dose group combinations. The combination with the lowest P-value was identified as the most promising and included in the multivariable analysis along with other clinical factors. The combinations of mean heart dose (MHD)/lung V40 (LV40) ('Vxx' denotes the percentage of organ volume receiving ≥xx Gy) and heart V5 (HV5)/LV40 yielded the lowest P-values (P = 0.021). The thresholds for these dose parameters were MHD ≤24.4 Gy, HV5 ≤63% and LV40 ≤7.7%, respectively. Multivariable analysis incorporating clinical factors identified age ≥65 years (HR: 2.06, P = 0.002), performance status ≥1 (Hazard ratio [HR]: 1.68, P = 0.024), chemoradiotherapy (HR: 0.28, P < 0.001), current smoking history (HR: 2.21, P < 0.001), gross tumor volume (HR: 1.43, P = 0.007) and the MHD/LV40 combination (HR: 2.35, P = 0.003) as independent prognostic factors. While exploratory, this study highlights the clinical significance of the MHD/LV40 combination as a prognostic factor; integrating these parameters radiotherapy for LA-NSCLC may improve patient outcomes.

Indexed as

Carcinoma, Non-Small-Cell LungHeartLungLung NeoplasmsAgedAged, 80 and overDose-Response Relationship, RadiationFemaleHumansMaleMiddle AgedRadiotherapy DosageRetrospective Studiescardiac toxicityheart doselocally advanced non-small cell lung carcinomamulticenter retrospective studyoverall survivalradiation oncology

Identifiers

PMID42132624
PMCPMC13400569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.